Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
BOSTON, Jan. 27, 2016 -- Topokine Therapeutics, the biotechnology company pioneering topical medications to contour the face and body, announced today that it has initiated a Phase 2 study of TAT4 Gel for reduction of nasolabial folds. Commonly known as laugh lines, nasolabial folds are a common sign of aging. They are typically treated with injectable dermal fillers.
TAT4 Gel is the second product in Topokine’s innovative pipeline of topical adipomodulatory medicines. Applied to the skin once daily, TAT4 acts pharmacologically to increase subcutaneous fat, thereby softening skin wrinkles and folds. As part of the randomized, placebo-controlled trial, patients are applying TAT4 Gel to their nasolabial folds for three months.
“Our faces lose volume as we age, which deepens nasolabial folds,” said Jody Levine, MD, FAAD, FAAP, a New York dermatologist recognized by New Beauty as one of the nation’s Top Beauty Doctors. “TAT4 was designed to enhance tissue volume by increasing subcutaneous fat.”
“Today, many patients and dermatologists rely on injectable dermal fillers to rejuvenate the skin,” said Michael Singer, MD, PhD, Topokine’s Chief Scientific Officer. “TAT4 is based on a simple concept—that instead of injecting foreign substances into the skin, a topical product can signal the patient’s own cells to reestablish a more youthful contour.”
About Topokine
Topokine is a clinical-stage biotechnology company developing topical prescription medications that act pharmacologically on adipocytes to contour the face and body. The company’s lead program, XAF5 Ointment, is in late-stage clinical development for reduction of undereye bags (steatoblepharon). Topokine’s pipeline also includes TAT4 Gel, which increases subcutaneous fat and is in Phase 2 development as a “topical filler” for reduction of laugh lines (nasolabial folds). The company’s assets are protected by over 75 issued and pending patents worldwide. For more information, visit www.topokine.com.
Contact: Matt Burke [email protected]
